Studies have shown that targeting cPLA2 inhibits gastric cancer and augments chemotherapy efficacy by suppressing the Ras/MEK/ERK and Akt/β-catenin pathways (Liao et al., 2021), which indicates that PLA2 may be one of the upstream regulations of RAS pathways. The gene discussed is MAP2K7; the disease is gastric cancer.